Search results for " oligodendroglioma"

showing 6 items of 6 documents

Oligodendroglioma cells shed microvesicles which contain TRAIL as well as molecular chaperones and induce cell death in astrocytes.

2011

Microvesicles (MVs) shed from G26/24 oligodendroglioma cells were previously reported to cause a reproducible, dose-dependent, inhibitory effect on neurite outgrowth, and eventually neuronal apoptosis, when added to primary cultures of rat cortical neurons. These effects were reduced but not abolished by functional monoclonal antibodies against Fas-L. In order to investigate whether MVs contain other factors able to induce cell death, we tested them for TRAIL and found clear evidence of its presence in the vesicles. This finding suggests the possibility that Fas-L and TRAIL cooperate in inducing brain cell death. Aimed at understanding the route through which the vesicles deliver their mess…

Cancer ResearchProgrammed cell deathNeuritemedicine.drug_classOligodendrogliomaCellCell CommunicationBiologyMonoclonal antibodyTNF-Related Apoptosis-Inducing LigandCell-Derived MicroparticlesmedicineAnimalsHSP70 Heat-Shock ProteinsRats WistarCells CulturedCell DeathVesicleHSC70 Heat-Shock ProteinsCell cycleMicrovesiclesRatsCell biologymedicine.anatomical_structureOncologyApoptosisAstrocytesCulture Media Conditionedmicrovesicles oligodendroglioma astrocytes TRAIL Hsp70Molecular Chaperones
researchProduct

Melanoma cells release extracellular vesicles which contain H1° RNA and RNA-binding proteins

2015

G26/24 oligodendroglioma cells produce EVs that contain pro-apoptotic proteins, such as FasL and TRAIL, able to induce neuronal- [1] and astrocytic- [2] death. Cancer cells release EVs [3] through which transferring proteins, such as extracellular matrix remodelling proteases [4], and H1°, a differentiation-specific histone [5]. By releasing H1°, cells could escape differentiation cues [5]. To verify the role of EVs in releasing specific proteins and mRNAs, in this study we used A375 melanoma cells. EVs were purified from cell culture media as previously reported [1, 2]. T1 RNase-protection assays were performed on total cell lysates and EVs, as described elsewhere [6]. RNA-binding proteins…

G26/24 oligodendroglioma cells extracellular vesicles EVs Histone H1.0 A375 melanoma cells myelin expression factor-2 (MYEF2)Settore BIO/10 - BiochimicaSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct

Strategies in Glioma-Surgery

2011

1.1 Epidemiology and classification of gliomas Malignant glioma is one of the most feared diseases in the industrialized nations. About 77% of all malignant tumors within the central nervous system are gliomas. There are about 18.000 newly diagnosed cases annually within the USA (9/100.000 inhabitants per year) and the disease causes about 13.000 deaths each year. Statistically this is a higher loss of life-time than all other tumor-entities together (Schwartzbaum et al., 2006). About 45-50% of these gliomas are histologically classified as gliobalstoma multiforme (GBM) the most aggressive type of glioma which is classified as WHO grade IV (following the classification of Kleihues et al., 2…

Oncologymedicine.medical_specialtybusiness.industryAnaplastic oligodendrogliomaGlioma surgeryNewly diagnosedDiseasemedicine.diseaseWell differentiatednervous system diseasesInternal medicineGliomaEpidemiologymedicinebusinessneoplasmsAnaplastic astrocytoma
researchProduct

Cancer cells can affect behaviour of neighbouring cells by transferring molecules through extracellular vesicles

2017

Most cells release into the extracellular space membrane-bound structures of different sizes, origin and composition, collectively called extracellular vesicles (EVs) [1]. Tumor cells are much more active than normal cells in producing EVs. Because of this property, they are able to transfer both nucleic acids and proteins to the surrounding normal cells, thus inducing in these latter at least some transformed behavior. We previously showed that EVs produced by G26/24 oligodendroglioma cells can horizontally transfer to their neighbours radioactive proteins [2]. In addition, EVs released by these cells contain pro-apoptotic proteins, such as TRAIL and Fas-Ligand, able to induce apoptosis in…

Settore BIO/10 - BiochimicaSettore BIO/06 - Anatomia Comparata E CitologiaExtracellular vesicles (EVs) G26/24 oligodendroglioma cells rat cortical neurons astrocytes H1.0 histone protein H1.0 mRNA myelin expression factor-2 (MYEF2)
researchProduct

Melanoma cells release extracellular vesicles which contain RNA-binding proteins able to bind the mRNA encoding histone H1°

2015

Extracellular vesicles (EVs) are produced by most prokaryotic and eukaryotic cells; tumour cells, however, release much higher amounts of EVs, which contain cancer-specific proteins and RNAs. Molecules carried by EVs are captured by surrounding cells, which then undergo profound phenotypic modifications. G26/24 oligodendroglioma cells release, for example, EVs containing FasL and TRAIL, which induce apoptosis in rat cortical neurons and astrocytes in culture. By metabolic labelling of cells, EV-mediated horizontal transfer of radioactive proteins was clearly demonstrated. Among the proteins present in EVs produced by oligodendroglioma cells, extracellular matrix remodelling proteases, and t…

Settore BIO/10 - BiochimicaSettore BIO/06 - Anatomia Comparata E CitologiaExtracellular vesicles (EVs) G26/24 oligodendroglioma cells xtracellular matrix remodelling proteases A375 melanoma cells H1° histone RNA-protein complexes myelin expression factor-2 (MYEF2)
researchProduct

RNA as a carrier of epigenetic information

2017

Both prokaryotic and eukaryotic cells release into the extracellular matrix membrane-bound structures of different sizes, origin and composition, collectively called extracellular vesicles (EVs) [1]. Tumor cells, in particular, use EVs to transfer both nucleic acids and proteins to the surrounding normal cells, thus inducing in them transformed behaviours or killing them. G26/24 oligodendroglioma cells, for example, transfer by EVs pro-apoptotic proteins, such as TRAIL and Fas-Ligand [2], extracellular matrix remodelling proteases (such as ADAMTS) [3], and even the H1.0 histone protein [4]. Another tumour cell line, with a different tissue origin (A375 melanoma cells) releases into the medi…

Settore BIO/10 - BiochimicaSettore BIO/06 - Anatomia Comparata E Citologiaextracellular vesicles (EVs) G26/24 oligodendroglioma cells extracellular matrix remodelling proteases H1.0 histone protein H1.0 mRNA A375 melanoma cells myelin expression factor-2 (MYEF2)
researchProduct